Generic Name and Formulations:
Methsuximide 300mg; caps.
Indications for CELONTIN:
Absence (petit mal) seizures refractory to other drugs.
Adults and Children:
Individualize. Initially 300mg once daily for the 1st week; may increase at weekly intervals by 300mg/day for 3 weeks based on response; max 1.2g daily. May be administered with other anticonvulsants.
Monitor blood counts periodically, esp. if signs/symptoms of infection develop. Hepatic or renal impairment; monitor urine and liver function tests. Monitor for new or worsening depression, suicidal thoughts and/or unusual changes in behavior; withdraw gradually if occur. May increase frequency of grand mal seizures when used alone in mixed seizure type. Avoid abrupt cessation. Pregnancy.
May potentiate phenytoin, phenobarbital; monitor periodically.
Nausea, vomiting, diarrhea, weight loss, abdominal pain, constipation, blood dyscrasias, confusion, depression, drowsiness, ataxia, dizziness, rash, urticaria, hyperemia, proteinuria, hematuria; rare: SLE, suicidal ideation, psychosis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation